SS
DNLI icon

SBI Securities’s Denali Therapeutics DNLI Stock Holding History

SBI Securities’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.2K Buy
1,448
+1,080
+293% +$22.2K ﹤0.01% 1281
2026
Q1 		$7.07K Sell
368
-854
-70% -$17K ﹤0.01% 1881
2025
Q4 		$20.2K Buy
1,222
+1,200
+5,455% +$20.3K ﹤0.01% 1439
2025
Q3 		$319 Buy
22
+17
+340% +$244 ﹤0.01% 3163
2025
Q2 		$70 Hold
5
– – ﹤0.01% 3638
2025
Q1 		$68 Hold
5
– – ﹤0.01% 3562
2024
Q4 		$102 Buy
+5
New +$128 ﹤0.01% 3450

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SBI Securities's DNLI Position: Q2 2026 in Review

SBI Securities increased its Denali Therapeutics (DNLI) stake by 293% in Q2 2026, buying an estimated $22.2K and bringing the position to 1,448 shares worth $37.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1281.

SBI Securities first reported a position in DNLI in Q4 2024 and has held it in 7 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • SBI Securities held 1,448 shares of Denali Therapeutics worth $37.2K as of Q2 2026.
  • SBI Securities bought 1,080 Denali Therapeutics shares in Q2 2026, an estimated $22.2K.
  • Denali Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1281 holding.
  • SBI Securities first reported a position in Denali Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.